Please wait while the formulary information is being retrieved.
ADIPEX-P (PHENTERMINE HCL)
- Weight loss management for obese patient (bmi >= 30)
- Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity
37.5 mg tablet
- 1 tablet (37.5 mg) by oral route once daily before breakfast
8 mg tablet
- 1 tablet (8 mg) by oral route 3 times per day 1/2 hour before meals
phentermine 37.5 mg tablet
- 1 tablet (37.5 mg) by oral route once daily before breakfast
phentermine 8 mg tablet
- 1 tablet (8 mg) by oral route 3 times per day 1/2 hour before meals
37.5 mg tablet
- 1 tablet (37.5 mg) by oral route once daily before breakfast
37.5 mg capsule
- 1 capsule (37.5 mg) by oral route once daily before breakfast
Weight loss management for obese patient (bmi >= 30)
- one-half tablet (18.75 mg) by oral route once daily before breakfast
- one-half tablet (18.75 mg) by oral route once daily 1-2 hours after breakfast
- one-half tablet (18.75 mg) by oral route 2 times per day before breakfast and after lunch
- 1 tablet (37.5 mg) by oral route once daily before breakfast
- 1 tablet (37.5 mg) by oral route once daily one or two hours after breakfast
- 1 capsule (37.5 mg) by oral route once daily before breakfast
- 1 capsule (37.5 mg) by oral route once daily one or two hours after breakfast
Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity
- one-half tablet (18.75 mg) by oral route once daily before breakfast
- one-half tablet (18.75 mg) by oral route once daily 1-2 hours after breakfast
- one-half tablet (18.75 mg) by oral route 2 times per day before breakfast and after lunch
- 1 tablet (37.5 mg) by oral route once daily before breakfast
- 1 tablet (37.5 mg) by oral route once daily one or two hours after breakfast
- 1 capsule (37.5 mg) by oral route once daily before breakfast
- 1 capsule (37.5 mg) by oral route once daily one or two hours after breakfast
- isocarboxazid
- Marplan
- Matulane
- methylene blue (antidote)
- Nardil
- Parnate
- phenelzine
- procarbazine
- tranylcypromine
Contraindicated
- amitriptyline
- amitriptyline-chlordiazepoxide
- amoxapine
- Amrix
- Anafranil
- Azilect
- bromocriptine
- cabergoline
- Cafergot
- clomipramine
- Compound 347
- cyclobenzaprine
- cyclobenzaprine with msm
- Cycloset
- D.h.e.45
- Datscan
- desipramine
- dihydroergotamine
- doxepin
- Eldepryl
- enflurane
- ergoloid
- Ergomar
- ergotamine tartrate
- ergotamine-caffeine
- Forane
- imipramine HCl
- imipramine pamoate
- ioflupane I 123
- isoflurane
- linezolid
- maprotiline
- methylergonovine
- Migergot
- Migranal
- Norpramin
- nortriptyline
- Pamelor
- Parlodel
- perphenazine-amitriptyline
- protriptyline
- Prudoxin
- rasagiline
- selegiline HCl
- sevoflurane
- Silenor
- Sojourn
- Surmontil
- Tabradol
- Terrell
- Tofranil
- Tofranil-pm
- trimipramine
- Ultane
- Vivactil
- Zelapar
- Zonalon
- Zyvox
Severe
Moderate
- Brisdelle
- Celexa
- citalopram
- Cymbalta
- desvenlafaxine
- desvenlafaxine fumarate
- desvenlafaxine succinate
- duloxetine
- Effexor Xr
- escitalopram oxalate
- Fetzima
- fluoxetine
- fluvoxamine
- Khedezla
- levomilnacipran
- Lexapro
- Luvox Cr
- milnacipran
- olanzapine-fluoxetine
- paroxetine HCl
- paroxetine mesylate
- Paxil
- Paxil Cr
- Pexeva
- Pristiq
- Prozac
- Prozac Weekly
- Sarafem
- Savella
- sertraline
- Symbyax
- venlafaxine
- Viibryd
- vilazodone
- Zoloft
- 30 day risk period post-myocardial infarction
- Angina
- Cardiac arrhythmia
- Chronic heart failure
- Drug abuse
- Glaucoma
- History of cerebrovascular accident
- Hyperthyroidism
- Lactating mother
- Pregnancy
- Severe uncontrolled hypertension
Contraindicated
- Alcoholism
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Psychotic disorder
Severe
Moderate
- Diabetes mellitus
- Kidney disease with reduction in GFR
- Mild hypertension
ADIPEX-P (PHENTERMINE HCL)
- Weight loss management for obese patient (bmi >= 30)
- Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity
- Hypertension
- Dysgeusia
- Insomnia
- Nervousness
- Xerostomia
More Frequent
Severe
Less Severe
- Allergic dermatitis
- Cardiac arrhythmia
- Urticaria
- Acute abdominal pain
- Agitation
- Blurred vision
- Constipation
- Diarrhea
- Dizziness
- Dysuria
- Euphoria
- Flushing
- Headache disorder
- Libido changes
- Palpitations
- Skin rash
- Tachycardia
- Tremor
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Drug-induced psychosis
- Myocardial ischemia
- Pulmonary hypertension
- Valvular heart disease
Less Severe
- Dysphoric mood
- Erectile dysfunction
- Hyperhidrosis
- Increased urinary frequency
- Nausea
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Phentermine
Safety and effectiveness in pediatric patients have not been established.
- 1 Day – 18 Years
- Safety and effectiveness in pediatric patients have not been established.
Phentermine
- Severity Level:
X
- Additional Notes: Serious adverse effects possible
Contraindicated
Phentermine
Insuff data avail; mw low, excretion possible; other amphetamines excreted
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insuff data avail; mw low, excretion possible; other amphetamines excreted |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Phentermine
Cardiovascular-Limited usage data in the elderly. Contraindicated in severe hypertension, coronary insufficiency or peripheral vascular disease. Renal-Urinary excretion of 62-85%. Use caution with renal impairment to minimize adverse events. Neuro/Psych-May worsen insomnia. Ocular-Contraindicated in patients with glaucoma.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Weight loss management for obese patient (bmi >= 30) | |
| E66 | Overweight and obesity |
| E66.0 | Obesity due to excess calories |
| E66.01 | Morbid (severe) obesity due to excess calories |
| E66.09 | Other obesity due to excess calories |
| E66.1 | Drug-induced obesity |
| E66.2 | Morbid (severe) obesity with alveolar hypoventilation |
| E66.8 | Other obesity |
| E66.9 | Obesity, unspecified |
| Z68.3 | Body mass index (BMi) 30-39, adult |
| Z68.30 | Body mass index (BMi) 30.0-30.9, adult |
| Z68.31 | Body mass index (BMi) 31.0-31.9, adult |
| Z68.32 | Body mass index (BMi) 32.0-32.9, adult |
| Z68.33 | Body mass index (BMi) 33.0-33.9, adult |
| Z68.34 | Body mass index (BMi) 34.0-34.9, adult |
| Z68.35 | Body mass index (BMi) 35.0-35.9, adult |
| Z68.36 | Body mass index (BMi) 36.0-36.9, adult |
| Z68.37 | Body mass index (BMi) 37.0-37.9, adult |
| Z68.38 | Body mass index (BMi) 38.0-38.9, adult |
| Z68.39 | Body mass index (BMi) 39.0-39.9, adult |
| Z68.4 | Body mass index (BMi) 40 or greater, adult |
| Z68.41 | Body mass index (BMi) 40.0-44.9, adult |
| Z68.42 | Body mass index (BMi) 45.0-49.9, adult |
| Z68.43 | Body mass index (BMi) 50.0-59.9, adult |
| Z68.44 | Body mass index (BMi) 60.0-69.9, adult |
| Z68.45 | Body mass index (BMi) 70 or greater, adult |
| Wt loss mgmt, pt with bmi 27-29 & wt-related comorbidity | |
| E66.3 | Overweight |
| Z68.27 | Body mass index (BMi) 27.0-27.9, adult |
| Z68.28 | Body mass index (BMi) 28.0-28.9, adult |
| Z68.29 | Body mass index (BMi) 29.0-29.9, adult |
| 0-9 | A-Z |
|---|---|
| E66 | Overweight and obesity |
| E66.0 | Obesity due to excess calories |
| E66.01 | Morbid (severe) obesity due to excess calories |
| E66.09 | Other obesity due to excess calories |
| E66.1 | Drug-induced obesity |
| E66.2 | Morbid (severe) obesity with alveolar hypoventilation |
| E66.3 | Overweight |
| E66.8 | Other obesity |
| E66.9 | Obesity, unspecified |
| Z68.27 | Body mass index (BMi) 27.0-27.9, adult |
| Z68.28 | Body mass index (BMi) 28.0-28.9, adult |
| Z68.29 | Body mass index (BMi) 29.0-29.9, adult |
| Z68.3 | Body mass index (BMi) 30-39, adult |
| Z68.30 | Body mass index (BMi) 30.0-30.9, adult |
| Z68.31 | Body mass index (BMi) 31.0-31.9, adult |
| Z68.32 | Body mass index (BMi) 32.0-32.9, adult |
| Z68.33 | Body mass index (BMi) 33.0-33.9, adult |
| Z68.34 | Body mass index (BMi) 34.0-34.9, adult |
| Z68.35 | Body mass index (BMi) 35.0-35.9, adult |
| Z68.36 | Body mass index (BMi) 36.0-36.9, adult |
| Z68.37 | Body mass index (BMi) 37.0-37.9, adult |
| Z68.38 | Body mass index (BMi) 38.0-38.9, adult |
| Z68.39 | Body mass index (BMi) 39.0-39.9, adult |
| Z68.4 | Body mass index (BMi) 40 or greater, adult |
| Z68.41 | Body mass index (BMi) 40.0-44.9, adult |
| Z68.42 | Body mass index (BMi) 45.0-49.9, adult |
| Z68.43 | Body mass index (BMi) 50.0-59.9, adult |
| Z68.44 | Body mass index (BMi) 60.0-69.9, adult |
| Z68.45 | Body mass index (BMi) 70 or greater, adult |
Formulary Reference Tool